Clinical Trial

Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression

Recruiting
View on ClinicalTrials.gov →
Summary
This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic. Participation in the study will involve adding coaching sessions to your existing ketamine maintenance treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-30.
Trial Details
NCT Number NCT07563868
Lead Sponsor Massachusetts General Hospital
Collaborators: Fireside Project
Conditions Treatment Resistant Depression (TRD)
Enrollment 20 participants
Start Date 2026-04-17
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-23